Table 2 Bivariate analysis with respect to first-week mortality
Variables | Alive | Died | p | ||
|---|---|---|---|---|---|
n | % | n | % | ||
Sex | |||||
Male | 389 | 84.0 | 74 | 16.0 | 0.276 |
Female | 252 | 87.2 | 37 | 12.8 | |
Age (years) | |||||
Mean – SD | 64.1 | 17.1 | 71.2 | 13.1 | <0.001 |
ESBL multi-resistance | |||||
Absent | 609 | 85.1 | 107 | 14.9 | 0.695 |
Present | 32 | 88.9 | 4 | 11.1 | |
Type of infection | |||||
Community-acquired | 270 | 86.8 | 41 | 13.2 | 0.371 |
Nosocomial | 137 | 82.0 | 30 | 18.0 | |
healthcare-associated | 234 | 85.4 | 40 | 14.6 | |
Source of infection | |||||
Absent | 45 | 73.8 | 16 | 26.2 | 0.014 |
Present | 596 | 86.3 | 95 | 13.7 | |
Treatment modification | |||||
Change to another drug | 343 | 89.3 | 41 | 10.7 | <0.001 |
Extension of duration | 27 | 96.4 | 1 | 3.6 | |
No change | 271 | 79.7 | 69 | 20.3 | |
McCabe | |||||
NF | 314 | 95.4 | 15 | 4.6 | <0.001 |
UF | 241 | 78.8 | 65 | 21.2 | |
RF | 86 | 74.1 | 30 | 25.9 | |
Pitt | |||||
0–2 | 569 | 90.6 | 59 | 9.4 | <0.001 |
≥ 3 | 72 | 58.5 | 51 | 41.5 | |
Charlson | |||||
0–2 | 374 | 91.4 | 35 | 8.6 | <0.001 |
≥ 3 | 267 | 78,1 | 75 | 21.9 | |